Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. more
Time Frame | TGTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.22% | -0.94% | -2.6% |
1-Month Return | -6.79% | -5.08% | -1.08% |
3-Month Return | 38.75% | -10.62% | 3.45% |
6-Month Return | 75.23% | -6.18% | 8.57% |
1-Year Return | 89.88% | 1.98% | 24.3% |
3-Year Return | 66.37% | -0.93% | 25.58% |
5-Year Return | 193.01% | 33.84% | 84.07% |
10-Year Return | 105.48% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 152.00K | 152.00K | 6.69M | 2.79M | 233.66M | [{"date":"2019-12-31","value":0.07,"profit":true},{"date":"2020-12-31","value":0.07,"profit":true},{"date":"2021-12-31","value":2.86,"profit":true},{"date":"2022-12-31","value":1.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 282.00K | 374.00K | 790.00K | 265.00K | 14.55M | [{"date":"2019-12-31","value":1.94,"profit":true},{"date":"2020-12-31","value":2.57,"profit":true},{"date":"2021-12-31","value":5.43,"profit":true},{"date":"2022-12-31","value":1.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (130.00K) | (222.00K) | 5.90M | 2.52M | 219.11M | [{"date":"2019-12-31","value":-0.06,"profit":false},{"date":"2020-12-31","value":-0.1,"profit":false},{"date":"2021-12-31","value":2.69,"profit":true},{"date":"2022-12-31","value":1.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (85.53%) | (146.05%) | 88.19% | 90.48% | 93.77% | [{"date":"2019-12-31","value":-91.21,"profit":false},{"date":"2020-12-31","value":-155.75,"profit":false},{"date":"2021-12-31","value":94.05,"profit":true},{"date":"2022-12-31","value":96.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 169.21M | 273.75M | 350.67M | 195.36M | 198.47M | [{"date":"2019-12-31","value":48.25,"profit":true},{"date":"2020-12-31","value":78.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":55.71,"profit":true},{"date":"2023-12-31","value":56.6,"profit":true}] |
Operating Income | (169.06M) | (273.59M) | (344.77M) | (192.84M) | 20.63M | [{"date":"2019-12-31","value":-819.34,"profit":false},{"date":"2020-12-31","value":-1326,"profit":false},{"date":"2021-12-31","value":-1670.96,"profit":false},{"date":"2022-12-31","value":-934.61,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | (9.10M) | (12.12M) | (8.97M) | (15.69M) | (20.19M) | [{"date":"2019-12-31","value":-910300000,"profit":false},{"date":"2020-12-31","value":-1211600000,"profit":false},{"date":"2021-12-31","value":-896900000,"profit":false},{"date":"2022-12-31","value":-1568700000,"profit":false},{"date":"2023-12-31","value":-2018600000,"profit":false}] |
Pre-Tax Income | (172.87M) | (279.38M) | (348.10M) | (198.34M) | 13.06M | [{"date":"2019-12-31","value":-1323.47,"profit":false},{"date":"2020-12-31","value":-2138.88,"profit":false},{"date":"2021-12-31","value":-2664.99,"profit":false},{"date":"2022-12-31","value":-1518.41,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | 6.48M | 6.50M | 7.45M | 5.50M | 390.00K | [{"date":"2019-12-31","value":86.91,"profit":true},{"date":"2020-12-31","value":87.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":73.76,"profit":true},{"date":"2023-12-31","value":5.23,"profit":true}] |
Income After Taxes | (179.35M) | (285.88M) | (355.55M) | (203.83M) | 12.67M | [{"date":"2019-12-31","value":-1415.3,"profit":false},{"date":"2020-12-31","value":-2255.98,"profit":false},{"date":"2021-12-31","value":-2805.81,"profit":false},{"date":"2022-12-31","value":-1608.51,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | (172.87M) | (279.38M) | (348.10M) | (182.65M) | 12.67M | [{"date":"2019-12-31","value":-1364.2,"profit":false},{"date":"2020-12-31","value":-2204.71,"profit":false},{"date":"2021-12-31","value":-2747.01,"profit":false},{"date":"2022-12-31","value":-1441.35,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (179.35M) | (285.88M) | (355.55M) | (203.83M) | 12.67M | [{"date":"2019-12-31","value":-1415.3,"profit":false},{"date":"2020-12-31","value":-2255.98,"profit":false},{"date":"2021-12-31","value":-2805.81,"profit":false},{"date":"2022-12-31","value":-1608.51,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | (1.98) | (2.27) | (2.63) | (1.46) | 0.01 | [{"date":"2019-12-31","value":-19800,"profit":false},{"date":"2020-12-31","value":-22700,"profit":false},{"date":"2021-12-31","value":-26300,"profit":false},{"date":"2022-12-31","value":-14600,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
TGTX | |
---|---|
Cash Ratio | 2.73 |
Current Ratio | 4.59 |
Quick Ratio | 3.91 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TGTX | |
---|---|
ROA (LTM) | -0.07% |
ROE (LTM) | -8.05% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TGTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.67 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.33 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TGTX | |
---|---|
Trailing PE | NM |
Forward PE | 23.36 |
P/S (TTM) | 18.93 |
P/B | 26.10 |
Price/FCF | NM |
EV/R | 18.61 |
EV/Ebitda | 846.50 |
PEG | NM |
TG Therapeutics Inc (TGTX) share price today is $32.26
Yes, Indians can buy shares of TG Therapeutics Inc (TGTX) on Vested. To buy TG Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TGTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of TG Therapeutics Inc (TGTX) via the Vested app. You can start investing in TG Therapeutics Inc (TGTX) with a minimum investment of $1.
You can invest in shares of TG Therapeutics Inc (TGTX) via Vested in three simple steps:
The 52-week high price of TG Therapeutics Inc (TGTX) is $36.84. The 52-week low price of TG Therapeutics Inc (TGTX) is $12.84.
The price-to-earnings (P/E) ratio of TG Therapeutics Inc (TGTX) is
The price-to-book (P/B) ratio of TG Therapeutics Inc (TGTX) is 26.10
The dividend yield of TG Therapeutics Inc (TGTX) is 0.00%
The market capitalization of TG Therapeutics Inc (TGTX) is $5.01B
The stock symbol (or ticker) of TG Therapeutics Inc is TGTX